Hardy Kagimoto

Hardy is an advisor to Saisei Ventures, participating in the investment process as a contributor to the investment advisory committee.
Hardy is founder, Chairman, CEO and majority shareholder of Healios K.K., a Tokyo-based, clinical-stage world leader in regenerative medicine and cell therapy.
Hardy is a tireless advocate for bringing the breakthroughs of regenerative medicine from promise to patients.
From his position at Healios, he is leading this effort on a global scale.
After founding Healios in 2011, Hardy led the listing of the company on the Tokyo Stock Exchange in 2015 and has grown its team to more than 130 people based in its Japan and United States offices.
Healios leverages the attractive Japanese regulatory framework for regenerative medicine to efficiently deliver results for patients, its partners, and stakeholders.
It is currently running clinical trials for ischemic stroke (Phase 2/3) and acute respiratory distress syndrome (Phase 2) using bone marrow-derived allogeneic adult stem cells.
At the same time, Healios has established a next generation gene-edited universal iPSC platform to address multiple areas of unmet medical need in the immuno-oncology, ophthalmology and liver disease fields.
Hardy is a Kyushu University hospital trained ophthalmologist.
Prior to founding Healios, he built and ran his first biotech company, Aqumen, from 2005 to 2011 and launched BBG250, for which he is one of the listed inventors, which gained global de-facto-standard status as a surgical adjuvant in the ophthalmology community and ultimately has gone on to receive FDA approval in the United States.
Hardy graduated from the Department of Medicine, Kyushu University School of Medicine (Degree: Bachelor of Medicine) in 2002 and obtained his medical license (Medical Doctor) in 2003.